Antibodies Against Egg- and Cell-Grown Influenza A(H3N2) Viruses in Adults Hospitalized During the 2017-2018 Influenza Season.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
24 05 2019
Historique:
received: 11 10 2018
accepted: 29 01 2019
pubmed: 6 2 2019
medline: 25 2 2020
entrez: 6 2 2019
Statut: ppublish

Résumé

Influenza vaccine effectiveness was low in 2017-2018, yet circulating influenza A(H3N2) viruses were antigenically similar to cell-grown vaccine strains. Notably, most influenza vaccines are egg propagated. Serum specimens were collected shortly after illness onset from 15 influenza A(H3N2) virus-infected cases and 15 uninfected hospitalized adults. Geometric mean titers against egg- and cell-grown influenza A/Hong Kong/4801/2014(H3N2) virus vaccine strains and representative circulating viruses (including A/Washington/16/2017) were determined by a microneutralization (MN) assay. Independent effects of strain-specific titers on susceptibility were estimated by logistic regression. MN titers against egg-grown influenza A/Hong Kong virus were significantly higher among vaccinated individuals (173 vs 41; P = 0.01). In unadjusted models, a 2-fold increase in titers against egg-grown influenza A/Hong Kong virus was not significantly protective (29% reduction; P = .09), but a similar increase in the cell-grown influenza A/Washington virus antibody titer (3C.2a2) was protective (60% reduction; P = .02). Higher egg-grown influenza A/Hong Kong virus titers were not significantly associated with infection, when adjusted for antibody titers against influenza A/Washington virus (15% reduction; P = .61). A 54% reduction in the odds of infection was observed with a 2-fold increase in titer against influenza A/Washington virus (P = not significant), adjusted for the titer against egg-grown influenza A/Hong Kong virus titer. Individuals vaccinated in 2017-2018 had high antibody titers against the egg-adapted vaccine strain and lower titers against circulating viruses. Titers against circulating but not egg-adapted strains were correlated with protection.

Sections du résumé

BACKGROUND
Influenza vaccine effectiveness was low in 2017-2018, yet circulating influenza A(H3N2) viruses were antigenically similar to cell-grown vaccine strains. Notably, most influenza vaccines are egg propagated.
METHODS
Serum specimens were collected shortly after illness onset from 15 influenza A(H3N2) virus-infected cases and 15 uninfected hospitalized adults. Geometric mean titers against egg- and cell-grown influenza A/Hong Kong/4801/2014(H3N2) virus vaccine strains and representative circulating viruses (including A/Washington/16/2017) were determined by a microneutralization (MN) assay. Independent effects of strain-specific titers on susceptibility were estimated by logistic regression.
RESULTS
MN titers against egg-grown influenza A/Hong Kong virus were significantly higher among vaccinated individuals (173 vs 41; P = 0.01). In unadjusted models, a 2-fold increase in titers against egg-grown influenza A/Hong Kong virus was not significantly protective (29% reduction; P = .09), but a similar increase in the cell-grown influenza A/Washington virus antibody titer (3C.2a2) was protective (60% reduction; P = .02). Higher egg-grown influenza A/Hong Kong virus titers were not significantly associated with infection, when adjusted for antibody titers against influenza A/Washington virus (15% reduction; P = .61). A 54% reduction in the odds of infection was observed with a 2-fold increase in titer against influenza A/Washington virus (P = not significant), adjusted for the titer against egg-grown influenza A/Hong Kong virus titer.
CONCLUSION
Individuals vaccinated in 2017-2018 had high antibody titers against the egg-adapted vaccine strain and lower titers against circulating viruses. Titers against circulating but not egg-adapted strains were correlated with protection.

Identifiants

pubmed: 30721982
pii: 5306481
doi: 10.1093/infdis/jiz049
pmc: PMC6534188
doi:

Substances chimiques

Antibodies, Viral 0
Antigens, Viral 0
Influenza Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1904-1912

Subventions

Organisme : NCIRD CDC HHS
ID : U01 IP000974
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002240
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
Clin Infect Dis. 2010 Nov 1;51(9):997-1004
pubmed: 20868284
Vaccine. 2019 Feb 28;37(10):1284-1292
pubmed: 30738647
J Infect Dis. 2016 Oct 1;214(7):1010-9
pubmed: 27190176
Cell. 2018 Apr 5;173(2):417-429.e10
pubmed: 29625056
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
Bioinformatics. 2015 Nov 1;31(21):3546-8
pubmed: 26115986
J Vis Exp. 2017 Nov 22;(129):
pubmed: 29286446
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
MMWR Morb Mortal Wkly Rep. 2018 Jun 08;67(22):634-642
pubmed: 29879098
J Infect Dis. 2018 Jul 2;218(3):347-354
pubmed: 29506129
J Virol Methods. 2014 Dec 15;210:7-14
pubmed: 25233882
J Infect Dis. 2019 Sep 13;220(8):1265-1275
pubmed: 30561689
N Engl J Med. 2017 Jun 22;376(25):2427-2436
pubmed: 28636855
Clin Infect Dis. 2016 Oct 15;63(8):1017-25
pubmed: 27369320
Nat Methods. 2012 Jul 30;9(8):772
pubmed: 22847109
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
J Infect Dis. 2015 Oct 15;212(8):1191-9
pubmed: 25858957
Influenza Other Respir Viruses. 2014 May;8(3):384-8
pubmed: 24483237
Nat Med. 2016 Dec;22(12):1465-1469
pubmed: 27820604
Cell Rep. 2015 Jul 7;12(1):1-6
pubmed: 26119736
J Infect Dis. 2013 Mar 15;207(6):974-81
pubmed: 23307936
Lancet. 1973 Mar 24;1(7804):623-5
pubmed: 4121842
Vaccine. 2012 Dec 17;31(1):190-5
pubmed: 23107591
PLoS Pathog. 2017 Oct 23;13(10):e1006682
pubmed: 29059230
PLoS One. 2014 Mar 25;9(3):e92153
pubmed: 24667168
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156

Auteurs

Min Z Levine (MZ)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Emily T Martin (ET)

Department of Epidemiology, University of Michigan School of Public Health.

Joshua G Petrie (JG)

Department of Epidemiology, University of Michigan School of Public Health.

Adam S Lauring (AS)

Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

Crystal Holiday (C)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Stacie Jefferson (S)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

William J Fitzsimmons (WJ)

Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

Emileigh Johnson (E)

Department of Epidemiology, University of Michigan School of Public Health.

Jill M Ferdinands (JM)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.

Arnold S Monto (AS)

Department of Epidemiology, University of Michigan School of Public Health.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH